Proliferative Vitreoretinopathy Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2018 to 2027

  • Published : May-2018
  • Tables : 96
  • Figures : 78
  • Category : Healthcare
  • No. of Pages : 170
  • Report Code : FACT795MR
  • Format : ppt

Proliferative vitreoretinopathy (PVR) remains the most commonly observed failure in the surgery of rhegmatogenous retinal detachment (RRD), albeit substantial efforts have been taken to better understand and manage the condition in the past. Basic research indicates that proliferative vitreoretinopathy illustrates scarring - end-stage of wound healing process, which occurs post-retinal detachment surgery. Current medical treatment for PVR has been directed toward the prevention of inflammation – first stage of wound-healing process, and inhibition of cell proliferation – second stage.

Surgery for proliferative vitreoretinopathy, at present, demonstrates high anatomical success rate, despite disappointing visual results. Utilization of adjunctive treatments for preventing cellular proliferation has been deemed effective in the treatment & prevention of PVR, or post-surgery recurrences. Proliferation control and strategies directed toward the improvement of visual outcome are imperative focus areas for future studies in PVR. In addition, researches on the peri-retinal and intra-retinal pathology of proliferative vitreoretinopathy have illustrated characteristic alterations, which will significantly influence surgical management and visual outcome.

proliferative vitreoretinopathy market

A recent Fact.MR report foresees the proliferative vitreoretinopathy market to record a moderate rise over the period of forecast (2018-2027). Revenues from treatment and management of proliferative vitreoretinopathy worldwide will reach nearly US$ 660 Mn by 2027-end.

Proliferative Vitreoretinopathy Market: Potential of Systemic Anti-TNFα Treatment in Reduction of PVR to Influence Future Developments

Lack of effective prophylaxis or treatment has made proliferative vitreoretinopathy one of the most devastating complications witnessed in RRD. TNFα has been implied in PVR development, which in turn necessitates blockade of this factor for reducing or preventing onset of proliferative vitreoretinopathy. However, systemic treatment of PVR using anti-TNFα entails several side-effects and risks, and employment of such drugs for PVR treatment is not yet justified. Researchers have sought indirect approaches for determination of effectiveness of anti-TNFα in protection against PVR development post-RRD surgery.

Despite sound principles on which the approaches are based, low prevalence of patients affected with RRD, chronic inflammatory diseases, and PVR has prevented researchers from drawing conclusions with regard to potential effectiveness of the anti-TNFα therapy as prophylactic treatment for preventing or reducing PVR incidences following RRD. However, these approaches hold promise in promoting future in-vivo studies, and randomizing clinical trials in humans with the help of more preclinical research.

Proliferative Vitreoretinopathy Market: New PVR Development Suppression & Prevention Methods to Underpin Growth

Proliferative vitreoretinopathy, an inflammatory fibrotic disease, stems from inflammatory milieu post-RRD, which in turn prevents retinal healing. Several studies aimed at suppressing or preventing the development of PVR are being conducted worldwide, with some of the recent ones elucidating effect of “substance P (SP),” and targeted use of non-steroidal anti-inflammatory drugs such as “lornoxicam.”

Research carried out on lornoxicam has not only demonstrated successful improvement in the condition of retina and choroid, but also reduced frequency of membrane formation significantly. Studies conducted on substance P have revealed that SP has the capability of inhibiting apoptosis, and epithelial-mesenchymal transition (EMT) induced by TNFα caused, thereby suppressing or preventing development of proliferative retinopathy.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

1. Executive Summary
1.1. Summarizing Key Findings
1.2. Trends and Developments
1.3. Strategic Themes
1.4. Highlighting Action Area – Wheel of Fortune 

2. Global Proliferative Vitreoretinopathy Market Overview
2.1. Introduction
2.2. Market Definition
2.3. Market Taxonomy and Segments Captured

3. Global Proliferative Vitreoretinopathy Market Outlook 
3.1. Market Size (US$ Mn) and Forecast, 2013-2027
3.2. Market Y-o-Y Growth
3.3. Forecast Factors and Relevance Impact

4. Global Proliferative Vitreoretinopathy Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
4.4. Trends

5. Supply Chain Assessment 

6. Actionable Insights and Analysis 
6.1. Competition Footprint Matrix
6.2. Scenario Forecast
6.3. PEST Analysis
6.4. Porter's Five Forces Analysis
6.5. Product Life Cycle Analysis
6.6. Investment Feasibility Matrix
6.7. Key Participants Market Presence (Intensity Map) By Region

7. Global Proliferative Vitreoretinopathy Market Analysis and Forecast by Type, 2013-2027
7.1. Analysis and Forecast By Drug Class
       7.1.1. Revenue (US$ Mn) Comparison, By Region
       7.1.2. Market Share Comparison, By Region
       7.1.3. Y-o-Y growth Comparison, By Region
7.2. Analysis and Forecast By Mode of Administration
       7.2.1. Revenue (US$ Mn) Comparison, By Region
       7.2.2. Market Share Comparison, By Region
       7.2.3. Y-o-Y growth Comparison, By Region
7.3. Analysis and Forecast By Distribution Channel
       7.3.1. Revenue (US$ Mn) Comparison, By Region
       7.3.2. Market Share Comparison, By Region
       7.3.3. Y-o-Y growth Comparison, By Region

8. North America Proliferative Vitreoretinopathy Market Analysis, 2013-2027
8.1. Revenue (US$ Mn) Comparison, By Country
       8.1.1. US Market Size & Forecast Value (US$ Mn)
       8.1.2. Canada Market Size & Forecast Value (US$ Mn)
8.2.  Revenue (US$ Mn), By Drug Class
8.3. Revenue (US$ Mn), By Mode of Administration
8.4. Revenue (US$ Mn), By Distribution Channel

9. Latin America Proliferative Vitreoretinopathy Market Analysis, 2013-2027
9.1. Revenue (US$ Mn), By Country
       9.1.1. Brazil Market Size & Forecast Value (US$ Mn)
       9.1.2. Mexico Market Size & Forecast Value (US$ Mn)
       9.1.3. Rest of Latin America Market Size & Forecast Value (US$ Mn)
9.2. Revenue (US$ Mn), By Drug Class
9.3. Revenue (US$ Mn), By Mode of Administration
9.4. Revenue (US$ Mn), By Distribution Channel

10. Europe Proliferative Vitreoretinopathy Market Size and Forecast, 2013-2027
10.1. Revenue (US$ Mn) Comparison, By Country 
       10.1.1. Germany Market Size and Forecast Value (US$ Mn)
       10.1.2. UK Market Size and Forecast Value (US$ Mn)
       10.1.3. Spain Market Size and Forecast Value (US$ Mn)
       10.1.4. France Market Size and Forecast Value (US$ Mn)
       10.1.5. Italy Market Size and Forecast Value (US$ Mn)
       10.1.6. Rest of Europe Market Size and Forecast Value (US$ Mn)
10.2. Revenue (US$ Mn) Comparison, By Drug Class 
10.3. Revenue (US$ Mn) Comparison, By Mode of Administration 
10.4. Revenue (US$ Mn) Comparison, By Distribution Channel 

11. Japan Proliferative Vitreoretinopathy Market Size and Forecast, 2013-2027
11.1. Japan Market Size and Forecast Value (US$ Mn)
11.2. Revenue (US$ Mn) Comparison, By Drug Class 
11.3. Revenue (US$ Mn) Comparison, By Mode of Administration 
11.4. Revenue (US$ Mn) Comparison, By Distribution Channel 

12. APEJ Proliferative Vitreoretinopathy Market Size and Forecast, 2013-2027
12.1. Revenue (US$ Mn) Comparison, By Country 
       12.1.1. China Market Size and Forecast Value (US$ Mn)
       12.1.2. India Market Size and Forecast Value (US$ Mn)
       12.1.3. Malaysia Market Size and Forecast Value (US$ Mn)
       12.1.4. Singapore Market Size and Forecast Value (US$ Mn)
       12.1.5. Australia Market Size and Forecast Value (US$ Mn)
       12.1.6. Rest of APEJ Market Size and Forecast Value (US$ Mn)
12.2. Revenue (US$ Mn) Comparison, By Drug Class 
12.3. Revenue (US$ Mn) Comparison, By Mode of Administration 
12.4. Revenue (US$ Mn) Comparison, By Distribution Channel 

13. MEA Proliferative Vitreoretinopathy Market Size and Forecast, 2013-2027
13.1. Revenue (US$ Mn) Comparison, By Country 
       13.1.1. GCC Market Size and Forecast Value (US$ Mn)
       13.1.2. South Africa Market Size and Forecast Value (US$ Mn)
       13.1.3. Israel Market Size and Forecast Value (US$ Mn)
       13.1.4. Rest of MEA Market Size and Forecast Value (US$ Mn)
13.2. Revenue (US$ Mn) Comparison, By Drug Class 
13.3. Revenue (US$ Mn) Comparison, By Mode of Administration 
13.4. Revenue (US$ Mn) Comparison, By Distribution Channel 

14. Competition Landscape, Company Share and Company Profiles
14.1. Company Share Analysis
14.2. Competition Dashboard
14.3. Company Profiles
       14.3.1. Novartis AG
       14.3.2. Regeneron Pharmaceuticals, Inc.
       14.3.3. Genentech, Inc.
       14.3.4. Pfizer, Inc.
       14.3.5. Allergan Plc
       14.3.6. Other Public and Private Players

15. Key Takeaways

16. Research Methodology

17. Disclaimer

TABLE 1 Global Proliferative Vitreoretinopathy Market Value (US$ Mn), 2013-2018
TABLE 2 Global Proliferative Vitreoretinopathy Market Value (US$ Mn), 2019-2027
TABLE 3 Global Proliferative Vitreoretinopathy Market Value (US$ Mn) and Y-o-Y, 2018-2027
TABLE 4 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2013-2018
TABLE 5 Global Anti-VEGF Agents Segment Value (US$ Mn), By Region 2019-2027
TABLE 6 Global Anti-VEGF Agents Segment Market Share, By Region 2013-2018
TABLE 7 Global Anti-VEGF Agents Segment Market Share, By Region 2019-2027
TABLE 8 Global Anti-VEGF Agents Segment Y-o-Y, By Region 2018-2027
TABLE 9 Global Corticosteroids Segment Value (US$ Mn), By Region 2013-2018
TABLE 10 Global Corticosteroids Segment Value (US$ Mn), By Region 2019-2027
TABLE 11 Global Corticosteroids Segment Market Share, By Region 2013-2018
TABLE 12 Global Corticosteroids Segment Market Share, By Region 2019-2027
TABLE 13 Global Corticosteroids Segment Y-o-Y, By Region 2018-2027
TABLE 14 Global Anti-TGF Beta Antibody Segment Value (US$ Mn), By Region 2013-2018
TABLE 15 Global Anti-TGF Beta Antibody Segment Value (US$ Mn), By Region 2019-2027
TABLE 16 Global Anti-TGF Beta Antibody Segment Market Share, By Region 2013-2018
TABLE 17 Global Anti-TGF Beta Antibody Segment Market Share, By Region 2019-2027
TABLE 18 Global Anti-TGF Beta Antibody Segment Y-o-Y, By Region 2018-2027
TABLE 19 Global Injectables Segment Value (US$ Mn), By Region 2013-2018
TABLE 20 Global Injectables Segment Value (US$ Mn), By Region 2019-2027
TABLE 21 Global Injectables Segment Market Share, By Region 2013-2018
TABLE 22 Global Injectables Segment Market Share, By Region 2019-2027
TABLE 23 Global Injectables Segment Y-o-Y, By Region 2018-2027
TABLE 24 Global Oral Segment Value (US$ Mn), By Region 2013-2018
TABLE 25 Global Oral Segment Value (US$ Mn), By Region 2019-2027
TABLE 26 Global Oral Segment Market Share, By Region 2013-2018
TABLE 27 Global Oral Segment Market Share, By Region 2019-2027
TABLE 28 Global Oral Segment Y-o-Y, By Region 2018-2027
TABLE 29 Global Others Segment Value (US$ Mn), By Region 2013-2018
TABLE 30 Global Others Segment Value (US$ Mn), By Region 2019-2027
TABLE 31 Global Others Segment Market Share, By Region 2013-2018
TABLE 32 Global Others Segment Market Share, By Region 2019-2027
TABLE 33 Global Others Segment Y-o-Y, By Region 2018-2027
TABLE 34 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2013-2018
TABLE 35 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2019-2027
TABLE 36 Global Hospital Pharmacies Segment Market Share, By Region 2013-2018
TABLE 37 Global Hospital Pharmacies Segment Market Share, By Region 2019-2027
TABLE 38 Global Hospital Pharmacies Segment Y-o-Y, By Region 2018-2027
TABLE 39 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2013-2018
TABLE 40 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2019-2027
TABLE 41 Global Retail Pharmacies Segment Market Share, By Region 2013-2018
TABLE 42 Global Retail Pharmacies Segment Market Share, By Region 2019-2027
TABLE 43 Global Retail Pharmacies Segment Y-o-Y, By Region 2018-2027
TABLE 44 Global Online Pharmacies Segment Value (US$ Mn), By Region 2013-2018
TABLE 45 Global Online Pharmacies Segment Value (US$ Mn), By Region 2019-2027
TABLE 46 Global Online Pharmacies Segment Market Share, By Region 2013-2018
TABLE 47 Global Online Pharmacies Segment Market Share, By Region 2019-2027
TABLE 48 Global Online Pharmacies Segment Y-o-Y, By Region 2018-2027
TABLE 49 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
TABLE 50 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
TABLE 51 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
TABLE 52 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
TABLE 53 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
TABLE 54 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
TABLE 55 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
TABLE 56 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
TABLE 57 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
TABLE 58 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
TABLE 59 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
TABLE 60 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
TABLE 61 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
TABLE 62 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
TABLE 63 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
TABLE 64 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
TABLE 65 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
TABLE 66 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
TABLE 67 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
TABLE 68 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
TABLE 69 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
TABLE 70 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
TABLE 71 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
TABLE 72 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
TABLE 73 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
TABLE 74 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
TABLE 75 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
TABLE 76 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
TABLE 77 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
TABLE 78 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
TABLE 79 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
TABLE 80 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
TABLE 81 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
TABLE 82 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
TABLE 83 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
TABLE 84 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
TABLE 85 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
TABLE 86 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
TABLE 87 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
TABLE 88 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
TABLE 89 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
TABLE 90 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
TABLE 91 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
TABLE 92 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
TABLE 93 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
TABLE 94 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
TABLE 95 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
TABLE 96 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027

FIG. 1 Global Proliferative Vitreoretinopathy Market Value (US$ Mn), 2013-2018
FIG. 2 Global Proliferative Vitreoretinopathy Market Value (US$ Mn) Forecast, 2019-2027
FIG. 3 Global Proliferative Vitreoretinopathy Market Value (US$ Mn) and Y-o-Y, 2018-2027
FIG. 4 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 5 Global Anti-VEGF Agents Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 6 Global Anti-VEGF Agents Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 7 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 8 Global Corticosteroids Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 9 Global Corticosteroids Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 10 Global Anti-TGF Beta Antibody Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 11 Global Anti-TGF Beta Antibody Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 12 Global Anti-TGF Beta Antibody Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 13 Global Injectables Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 14 Global Injectables Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 15 Global Injectables Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 16 Global Oral Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 17 Global Oral Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 18 Global Oral Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 19 Global Others Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 20 Global Others Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 21 Global Others Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 22 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 23 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 24 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 25 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 26 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 27 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 28 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2013-2018
FIG. 29 Global Online Pharmacies Segment Market Value (US$ Mn) By Region, 2019-2027
FIG. 30 Global Online Pharmacies Segment Y-o-Y Growth Rate, By Region, 2018-2027
FIG. 31 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
FIG. 32 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
FIG. 33 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
FIG. 34 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
FIG. 35 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
FIG. 36 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
FIG. 37 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
FIG. 38 North America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
FIG. 39 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
FIG. 40 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
FIG. 41 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
FIG. 42 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
FIG. 43 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
FIG. 44 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
FIG. 45 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
FIG. 46 Latin America Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
FIG. 47 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
FIG. 48 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
FIG. 49 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
FIG. 50 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
FIG. 51 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
FIG. 52 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
FIG. 53 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
FIG. 54 Europe Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
FIG. 55 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
FIG. 56 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
FIG. 57 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
FIG. 58 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
FIG. 59 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
FIG. 60 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
FIG. 61 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
FIG. 62 Japan Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
FIG. 63 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
FIG. 64 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
FIG. 65 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
FIG. 66 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
FIG. 67 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
FIG. 68 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
FIG. 69 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
FIG. 70 APEJ Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027
FIG. 71 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2013-2018
FIG. 72 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Country 2019-2027
FIG. 73 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2013-2018
FIG. 74 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Drug Class 2019-2027
FIG. 75 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2013-2018
FIG. 76 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Mode of Administration 2019-2027
FIG. 77 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2013-2018
FIG. 78 MEA Proliferative Vitreoretinopathy Market Value (US$ Mn), By Distribution Channel 2019-2027

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Benefits of Becoming a Fact.MR Client

  • Access to our global market coverage
  • Periodic updates on your sector
  • Exclusive discounts and offers
  • Greater flexibility for customization
  • Quick-research assistance for ad-hoc needs
  • Access to credible insights Fact.MR analyst interactions
  • Access to Fact.MR tools and research to fuel strategy development